An official website of the United States government.

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

National Agricultural Library
U.S. Department of Agriculture
  1. Home
  2. Human Nutrition and Food Safety
  3. Research Publications (Food Safety)

Research Publications (Food Safety)

This page tracks research articles published in national and international peer-reviewed journals. Recent articles are available ahead of print and searchable by Journal, Article Title, and Category. Research publications are tracked across six categories: Bacterial Pathogens, Chemical Contaminants, Natural Toxins, Parasites, Produce Safety, and Viruses. Articles produced by USDA Grant Funding Agencies (requires login) and FDA Grant Funding Agencies (requires login) are also tracked in Scopus.

Displaying 1 - 25 of 46

  1. The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA COVID‐19 vaccine

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  2. The form of PEG matters: PEG conjugated with lipids and not PEG alone could be the specific form involved in allergic reactions to COVID‐19 vaccines

    • Allergy

    • Allergy, Accepted Article.

      • Viruses
      • COVID-19

  3. COVID‐19 vaccines tolerated in patients with paclitaxel and docetaxel allergy

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  4. Childhood BCG vaccination seems to selectively protect adult males from COVID‐19 infection

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  5. Mast cell activation is associated with post‐acute COVID‐19 syndrome

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  6. Experience with polyethylene glycol allergy‐guided risk management for COVID‐19 vaccine anaphylaxis

    • Allergy

    • Allergy, EarlyView.

      • Viruses
      • COVID-19

  7. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID‐19 vaccines in Europe

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 72-82, January 2022.

      • Viruses
      • COVID-19

  8. COVID‐19 vaccines—The way forward

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 15-16, January 2022.

      • Viruses
      • COVID-19

  9. COVID‐19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 304-307, January 2022.

      • Viruses
      • COVID-19

  10. Antiviral response in vernal keratoconjunctivitis may be protective against COVID‐19

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 298-300, January 2022.

      • Viruses
      • COVID-19

  11. Adding the variable of environmental complexity into the COVID‐19 pandemic equation

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 331-333, January 2022.

      • Viruses
      • COVID-19

  12. Successful administration of second dose of BNT162b2 COVID‐19 vaccine in two patients with potential anaphylaxis to first dose

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 337-338, January 2022.

      • Viruses
      • COVID-19

  13. Asthma phenotypes, associated comorbidities, and long‐term symptoms in COVID‐19

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 173-185, January 2022.

      • Viruses
      • COVID-19

  14. Caspases and therapeutic potential of caspase inhibitors in moderate–severe SARS‐CoV‐2 infection and long COVID

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 118-129, January 2022.

      • Viruses
      • COVID-19

  15. Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 258-270, January 2022.

      • Viruses
      • COVID-19

  16. Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 282-295, January 2022.

      • Viruses
      • COVID-19

  17. One Health: EAACI Position Paper on coronaviruses at the human‐animal interface, with a specific focus on comparative and zoonotic aspects of SARS‐CoV‐2

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 55-71, January 2022.

      • Viruses
      • COVID-19

  18. Adherence to subcutaneous immunotherapy with aeroallergens in real‐life practice during the COVID‐19 pandemic

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 197-206, January 2022.

      • Viruses
      • COVID-19

  19. Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction

    • Allergy

    • Allergy, Volume 77, Issue 1, Page 143-149, January 2022.

      • Viruses
      • COVID-19

  20. Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement

    • Allergy
      • Viruses
      • COVID-19

  21. Distribution of ACE2, CD147, CD26 and other SARS‐CoV‐2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID‐19 risk factors

    • Allergy

    • Background Morbidity and mortality from COVID‐19 caused by novel coronavirus SARS‐CoV‐2 is accelerating worldwide and novel clinical presentations of COVID‐19 are often reported. The range of human cells and tissues targeted by SARS‐CoV‐2, its potential receptors and associated regulating factors are still largely unknown.

      • Viruses
      • COVID-19

  22. Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement

    • Allergy

    • The outbreak of the SARS‐CoV‐2‐induced Coronavirus Disease 2019 (COVID‐19) pandemic re‐shaped doctor‐patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant numberof the patients are on treatment with biologicals and clinicians face the challenge to provide optimal care during the pandemic.

      • Viruses
      • COVID-19

  23. Clinical characteristics of 182 pediatric COVID‐19 patients with different severities and allergic status

    • Allergy

    • Background The pandemic of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection has made widespread impact recently. We aim to investigate the clinical characteristics of COVID‐19 children with different severities and allergic status.

      • Viruses
      • COVID-19

  24. COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic – an EAACI/ARIA Position Paper

    • Allergy

    • Background The Coronavirus disease 2019 (COVID‐19) has evolved as a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS‐CoV‐)2. Allergists and other health care providers (HCPs) in the field of allergies and associated airway diseases are in the front line, taking care of patients potentially infected with SARS‐CoV‐2.

      • Viruses
      • COVID-19

  25. Immunology of COVID‐19: mechanisms, clinical outcome, diagnostics and perspectives – a report of the European Academy of Allergy and Clinical Immunology (EAACI)

    • Allergy

    • With the worldwide spread of the novel Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) resulting in declaration of a pandemic by the World Health Organization (WHO) on March 11, 2020, the SARS‐CoV‐2‐induced Coronavirus disease‐19 (COVID‐19) has become one of the main challenges of our times. The high infection rate and the severe disease course led to major safety and social restriction measures worldwide.

      • Viruses
      • COVID-19